Vividion Therapeutics

Company Drug

Bayer’s Vividion Therapeutics Starts Phase I Study for RAS-PI3Kα Inhibitor

Fineline Cube Apr 7, 2025

German pharmaceutical giant Bayer’s (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the...

Company Deals Drug

Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial

Company Drug

Chengdu Kanghong Gains NMPA Approval for KH815 in Advanced Solid Tumors

Company Drug

Avistone’s Vebreltinib and PLB1004 Receive CDE Breakthrough Therapy Designation for NSCLC

Company Deals

Shanghai Pharmaceuticals’ RMB 4.66 Billion M&A Fund Completes AMAC Registration